COVID-19 Respiratory Drug Maker Named In Investor Suit Over EUA Misstatements
WILMINGTON, Del. — A clinical-stage small molecule pharmaceutical company and two of its senior officers violated federal securities laws by misrepresenting the likelihood that the company’s COVID-19 respiratory failure treatment drug...To view the full article, register now.
Already a subscriber? Click here to view full article